Obviously, this doesn't have anything to do with BTIM's long term potential or basic science, and I'm not even sure whether it is just perception or reflects reality, but it seems like BTIM had an over abundance of press releases with respect to their Phase III hextend trial, e.g. "BTIM has finished its trial", "BTIM will present its results at xxx meeting", "BTIM is unblinding its results", etc. There's no beef here. In terms of the blood substite-like and blood-safety companies I've looked at, BTIM is clearly the most hype-prone, and I don't think this is such a good thing. Biotime may have a good product, but so much hype breeds unrealistic expectations, and anytime those expectations aren't met, the stock takes a bigger hit than it should.